Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy

被引：0
|
作者：
Chen, P. -W. [1 ]
Ho, M. -Y. [2 ]
Feng, W. -H. [3 ]
Su, C. -H. [4 ]
Huang, S. -W. [4 ]
Cheng, C. -W. [5 ]
Yeh, H. -I. [5 ]
Chen, C. -P. [6 ]
Huang, W. -C. [7 ]
Fang, C. -C. [8 ]
Lin, H. -W. [1 ]
Lin, S. -H. [1 ]
Hsieh, I. -C. [2 ]
Li, Y. -H. [1 ]
机构：
[1] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[2] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, taoyuan, Taiwan
[3] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan
[4] Chung Shan Med Univ Hosp, Taichung, Taiwan
[5] Mackay Mem Hosp, Taipei, Taiwan
[6] Changhua Christian Hosp, Changhua, Taiwan
[7] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan
[8] Tainan Municipal Hosp, Tainan, Taiwan
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1208 / 1208
页数：1
相关论文
共 50 条
  • [31] P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease
    Bierend, Anneke
    Rau, Thomas
    Maas, Renke
    Schwedhelm, Edzard
    Boeger, Rainer H.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (04) : 540 - 547
  • [32] DURATION AND TIMING OF INITIATION OF THERAPY WITH PLATELET P2Y12 INHIBITORS IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
    Shalaev, S., V
    Safiullina, Z. M.
    KARDIOLOGIYA, 2018, 58 (03) : 54 - 62
  • [33] In established atherosclerosis, P2Y12 inhibitor vs. aspirin monotherapy reduces MI but not stroke or mortality
    Elgendy, Islam Y.
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (06) : JC26 - JC26
  • [34] P2Y12 inhibitor in acute coronary syndromes
    Wiwanitkit, Viroj
    NATIONAL MEDICAL JOURNAL OF INDIA, 2013, 26 (04): : 249 - 249
  • [35] Choosing between aspirin or P2Y12 monotherapy after short course of DAPT
    Kuno, Toshiki
    Ueyama, Hiroki
    Takagi, Hisato
    Bangalore, Sripal
    Kumari, Vimla
    AMERICAN HEART JOURNAL, 2020, 230 : 100 - 100
  • [36] Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
    Tantry, Udaya S.
    Navarese, Eliano P.
    Myat, Aung
    Gurbel, Paul A.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2018, 60 (4-5) : 460 - 470
  • [37] Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis
    Luna Carrillo-Aleman
    Francisco Marín
    José M. Rivera-Caravaca
    Nuria Vicente-Ibarra
    Elena Candela-Sanchez
    Maria A. Esteve-Pastor
    Teresa Lozano
    Miriam Sandín-Rollan
    Vicente Pernias-Escrig
    Manuel Macías
    Miriam Quintana-Giner
    Andrea Veliz
    Esteban Orenes-Piñero
    Juan G. Martínez-Martínez
    Juan M. Ruiz-Nodar
    Clinical Drug Investigation, 2019, 39 : 275 - 283
  • [38] Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis
    Carrillo-Aleman, Luna
    Marin, Francisco
    Rivera-Caravaca, Jose M.
    Vicente-Ibarra, Nuria
    Candela-Sanchez, Elena
    Esteve-Pastor, Maria A.
    Lozano, Teresa
    Sandin-Rollan, Miriam
    Pernias-Escrig, Vicente
    Macias, Manuel
    Quintana-Giner, Miriam
    Veliz, Andrea
    Orenes-Pinero, Esteban
    Martinez-Martinez, Juan G.
    Ruiz-Nodar, Juan M.
    CLINICAL DRUG INVESTIGATION, 2019, 39 (03) : 275 - 283
  • [39] P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention
    Zhou, Xuan
    Angiolillo, Dominick J.
    Ortega-Paz, Luis
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2022, 9 (10)
  • [40] P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
    Ando, Giuseppe
    De Santis, Giulia Azzurra
    Greco, Antonio
    Pistelli, Lorenzo
    Francaviglia, Bruno
    Capodanno, Davide
    De Caterina, Raffaele
    Capranzano, Piera
    JACC-CARDIOVASCULAR INTERVENTIONS, 2022, 15 (22) : 2239 - 2249
12345